Leveraging genetic ancestry continuum information to interpolate PRS for admixed populations

Yunfeng Ruan[1], Rohan Bhukar[1,2], Aniruddh Patel[1,2,3], Satoshi Koyama[1,2,3,4], Leland Hull[5,6], Buu Truong[1,2,3,8], Whitney Hornsby[1,2], Haoyu Zhang[7], Nilanjan Chatterjee[9,10], Pradeep Natarajan[1,2,3,6]

Affiliations:
1. Program in Medical and Population, Genetics and Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, MA, USA
2. Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA
3. Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA, USA
4. Laboratory for Cardiovascular Genomics and Informatics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
5. Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA
6. Department of Medicine, Harvard Medical School, Boston, MA, USA
7. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
8. Department of Genetic Epidemiology and Statistical Genetics, Harvard T.H. School of Public Health, Cambridge, MA, US
9. Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
10. Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA

Please address correspondence to:
Pradeep Natarajan, MD MMSc
185 Cambridge Street, CPZN 5.238
Boston, MA 02446
617-726-1843
pnatarajan@mgh.harvard.edu

Funding:
P.N. is supported by NHGRI U01HG011719 and NHLBI R01HL127564. N.C is supported by NHGRI U01HG011719 and R01HG010480.

Disclosures:
P.N. reports research grants from Allelica, Amgen, Apple, Boston Scientific, Genentech / Roche, and Novartis, personal fees from Allelica, Apple, AstraZeneca, Blackstone Life Sciences, Creative Education Concepts, CRISPR Therapeutics, Eli Lilly & Co, Esperion Therapeutics, Foresite Capital, Foresite Labs, Genentech / Roche, GV, HeartFlow, Magnet Biomedicine, Merck, Novartis, TenSixteen Bio, and Tourmaline Bio, equity in Bolt, Candela, Mercury, MyOme, Parameter Health, Preciseli, and TenSixteen Bio, and spousal employment at Vertex Pharmaceuticals, all unrelated to the present work.

Abstract

Calculating optimal polygenic risk scores (PRS) across diverse ancestries,
particularly in admixed populations, is necessary to enable equitable genetic
research and clinical translation. However, the relatively low representation of
admixed populations in both discovery and fine-tuning individual-level datasets limits
PRS development for admixed populations. Under the assumption that the most
informative PRS weight for a homogeneous sample, which can be approximated by a
data point in the ancestry continuum space, varies linearly in that space, we
introduce a Genetic Distance-assisted PRS Combination Pipeline for Diverse Genetic
Ancestries (**DiscoDivas**) to interpolate a harmonized PRS for diverse, especially
admixed, ancestries, leveraging multiple PRS weights fine-tuned within single-
ancestry samples and the genetic ancestry continuum information. DiscoDivas treats
ancestry as a continuous variable and does not require shifting between different
models when calculating PRS for different ancestries. We generated PRS with
DiscoDivas and the current conventional method, i.e. fine-tuning multiple GWAS PRS
using the matched or similar ancestry sample, for simulated datasets and large-scale
biobank datasets (UK Biobank [UKBB] N=415,402, Mass General Brigham Biobank
N=53,306, *All of Us* N=245,394) and compared our method with the conventional
method with quantitative traits and complex disease traits. DiscoDivas generated a
harmonized PRS of the accuracy comparable to or higher than the conventional
approach, with the greatest advantage exhibited in admixed samples: DiscoDivas
PRS for admixed samples was more statistically accurate than the PRS fine-tuned in
matched or similar ancestry sample in 12 out of 16 simulated scenarios and was
statistically equivalent in the remaining four scenarios; when tested with quantitative
trait data in UKBB, DiscoDivas increased the PRS accuracy of admixed sample by
5% on average; yet no statistical difference was observed when tested for binary
traits in UKBB where ancestry-matched data was available. For the single ancestry
samples, the accuracy of DiscoDivas PRS and PRS fine-tuned in match samples
was similar. In summary, our method DiscoDivas yields a harmonized PRS of robust
accuracy for individuals across the genetic ancestry spectrum, including where
ancestry-matched training data may be incomplete.
81

Introduction/Main

Individuals not of European ancestry remain underrepresented in GWAS, which at
least partly explains why PRS performance is generally reduced among those of non-
European versus European ancestry[1]. Within the constraints of existing data, the
current principal solution to increase the PRS accuracy among non-European
individuals is to fine-tune a combination of PRS derived from multiple populations or
multiple traits with the individual-level data of a validation sample[2–6]. However, PRS
accuracy decays as the genetic distance between the testing and validation samples
increases[7]. Relative to the vast diversity across the genetic ancestry continuum, the
existing and near-term individual-level datasets that can be used for fine-tuning PRS
combinations remains very sparse. Most existing individual-level genotype data are
mainly collected from single-ancestry populations and therefore admixed populations
are left underrepresented and largely unaddressed[8–11]. Additionally, testing and
validation samples that are labeled as "from the same superpopulation" are often
truly genetically heterogeneous[10,12–15], leading to variable accuracy within such
samples.
98

PRS analysis across diverse ancestries may also be limited by inconsistency. The
raw PRS distributions of the same model varies by ancestry and therefore the raw
PRS values for individuals of different genetic ancestries should not be directly
compared without ancestry correction[16–18]. Although prior research[16,18,19] has shown
that regressing out the top principal components of ancestry (PCA) from the PRS can
unify the PRS distributions of different ancestries (i.e., the mean and standard
deviation of corrected PRS sampled from different populations can become very
close), the inconsistency is only partially solved. In the application of PRS across
diverse ancestries, one would have to use one PRS model for all the individuals,
causing inconsistent PRS accuracy, or use several discrete PRS models for different
individuals approximating superpopulations causing inconsistent PRS modelling and
accuracy.
111
Given these issues and the increasing clinical use of PRS[20–22], PRS generation for
diverse genetic ancestries with more consistent accuracy and more unified PRS
distributions is critically needed. We devised a method, DiscoDivas, a Genetic
*Dis*tance-assisted PRS *Co*mbination Pipeline for *Div*erse Genetic *A*ncestrie*s*, to
generate PRS across the genetic ancestry continuum. This method is based on the
recent observation[7] that the PRS accuracy in the testing data decays approximately
linearly as the genetic distance between the testing and validation samples
increases, and that the genetic distance can be approximated by Euclidian distance
of PCA based on the global ancestries[7]. Based on this observation, we assumed that
the most informative PRS weights for a sample can be linearly interpolated from the
currently available PRS weights that are fine-tuned in the ancestries surrounding it in
the global ancestry-based PCA space with the interpolation weights based on the
Euclidian distance of the PCA. In summary, DiscoDivas calculates PRS for diverse
genetic ancestries whose genetic data may not be sufficiently powerful to train the
PRS model by linearly interpolating the multiple PRS fine-tuned in ancestries whose
genetic data are more available. We evaluated its performance in simulated and
empiric data.
129

Results

Overview of DiscoDivas

DiscoDivas combines PRS fine-tuned in different validation samples - generally from
different single-ancestry populations - to linearly interpolate PRS for individuals of
diverse genetic ancestries, treating the ancestry information as a continuous variable.
The rationale for PRS combination is based on the observation that the correlation of
the most informative PRS weight for two samples of different ancestry drops as the
genetic distance, represented by Euclidean distance of global ancestry-based PCA,
increases[7]. Therefore, the best PRS weight for an ancestry representation can be
linearly interpolated from other PRS weights fine-tuned in other ancestries with the
additional consideration of the genetic distance between the samples.
141
Under the same principle of interpolating the PRS weight, the best PRS can be
interpolated from several PRS calculated using the weight fine-tuned in other
ancestries. Since generating individual-specific PRS weights in a testing dataset
causes redundant calculation and given the difficulty of normalizing information from
different datasets, we combine the PRS instead of the SNP weights. The PRS of

individuals in the testing sample is a linear combination of PRS based on the SNP
weights fine-tuned in different validation samples:

$$PRS_i = \sum w_{i,k} PRS_{i,k}$$

where $PRS_{i,k}$ is the PRS of testing individual i calculated using the weight fine-tuned
in validation sample k; $w_{i,k}$ is the combination coefficient mainly based on the
reciprocal of the PCA Euclidean distance between the testing individual and median
point of validation sample D_{i-k}. Note that the input PRS and PCA should be of the
same scale: all the individuals are projected to the same PCA space based on a
global ancestry reference panel and the PRS input $PRS_{i,k}$ is the raw PRS regressed
out the top PCs and then standardized.

In addition to the PCA distances, other factors are included in the model. First, since
some fine-tuning samples are more correlated than others (e.g., EAS and SAS are
more correlated than AFR and EUR), the combination coefficients should be further
modified by these correlations, which can also be extracted from the PCA Euclidean
distances. Second, since PRS fine-tuned in each of the validation samples may be of
differing qualities (e.g., when the PRS model fine-tuned in different samples are
based on GWAS of different sample sizes or populations), the quality of the PRS
trained with each of the training data will vary and should be taken into account when
combining the PRS. Thus, the combination coefficient $w_{i,k}$ in the previous formula is
a function of multiple factors:

$$w_{i,k} = f\left(\frac{1}{D_{i-k}}, G, r_k\right)$$

169 where $\frac{1}{D_{i-k}}$ is the reciprocal of PCA Euclidean distance between the individual i and
170 the validation sample k; G is the matrix of PCA Euclidean distance between
171 validation samples; r_k is the parameter describing the quality of validation samples. A
172 more detailed description of implementing DiscoDivas is given in the Method session.

Overview of multi-population GWAS PRS model

175
Figure 1: The workflow of comparing DiscoDivas with the existing method.

Left: The ideal situation for the existing method is to fine-tune a PRS model that contains multiple
GWAS with matched validation data, which is not currently available for many under-represented
populations. Right: DiscoDivas first fine-tunes the PRS in the available ancestries, which are currently
AFR, EAS, EUR, and SAS, and interpolates PRS for diverse ancestry groups based on these fine-tuned

PRS. In this plot, POP refers to any ancestry for which the PRS is to be calculated.
182

A common approach for constructing PRS is to include as much genome-wide
association study (GWAS) summary statistic data as possible in the discovery
data[5,23,24]. The GWAS data is typically then processed by PRS methods that will
adjust the SNP effect size using a set of hyper-parameters. Individual-level data of an
independent validation sample is used to fine-tune the hyper-parameters across PRS
methods and the combination of the fine-tuned PRS. The resulting PRS is expected
to perform the best in samples of matched ancestry with the validation sample.
190

The current approach, as shown in the left panel of Figure 1, is to use the multi-
GWAS PRS fine-tuned in the matched sample or the closest approximation when the
matched sample is unavailable. The pipeline of adjusting SNP effect sizes and
combining information from different GWAS varies widely. Without loss of generality,
we built the following pipeline as a representation of the current conventional method:
we first adjusted the SNP effect size of each of the summary statistical GWAS
datasets by a Bayesian method and then chose the most predictive PRS from all the
PRS generated under different hyper-parameters. For simulated GWAS data, we
used PRS-CS[25] to adjust the SNP effect size and LDpred2[26] for real GWAS. Then
we used the validation data to first select the most predictive PRS based on each
GWAS and then to train the linear combination of the most predictive single-GWAS
PRS with a linear regression model. The final PRS model generated from each of the
validation datasets is a linear combination of PRS. For the empiric data set, the PRS
were fine-tuned controlling for the following covariates: top 20 PCA, sex, and age.
We used AFR, EAS, EUR, SAS, AMR, and admixed samples to fine-tune the PRS.
206

On top of the conventional method, DiscoDivas calculates PRS of any ancestry using
a linear combination of a group of PRS fine-tuned in currently available samples as
shown in the right panel of Figure 1. The PRS input for DiscoDivas in this study was
the multi-GWAS PRS fine-tuned in AFR, EAS, EUR, and SAS validation samples
with the conventional method pipeline as mentioned above. The interpolation of
these four PRS is based on the PCA calculated using the 1000 Genomes reference
panel. For most of the PRS analysis conducted in in the present study, the input PRS
of DiscoDivas are based on the same set of discovery GWAS and the validation
datasets are sufficiently large to generate a stable result. Therefore, we assumed
that all the input PRS can be viewed as of equal quality and their parameter for PRS
quality A_k can be viewed as a constant value in the present study.
218

Simulated data results

Summary-level GWAS used as discovery data were generated based on simulated
genotype data based on 1000 Genomes reference as described in the previous
publication provided by Zhang et al[6]. The phenotypes were based on 100, 300,
1,000, or 10,000 causal SNPs randomly selected from the 1.4 million Hapmap3
SNPs to represent traits of different polygenicity. The per-allele effect sizes of the
causal SNPs followed a normal distribution, and the heritability was set as 0.6.
Scenarios where both casual SNPs and effect sizes were constant across the
populations and where the casual SNPs were shared but the effect sizes varied
across the populations were simulated. We used up to 100,000 simulated individuals
from AFR, EAS, EUR, and SAS to generate the discovery summary statistic GWAS
dataset with PLINK2[27] and left the remaining samples out for other downstream
analyses.

Validation and testing samples were also simulated based on UKBB genotype data
with the phenotypes simulated using the same pipeline and parameters as described
above. UKBB participants were divided by genetic ancestry using 1000 Genomes as
a reference. In addition to the groups of AFR, EAS, EUR, SAS, and AMR whose PCA
information were matched with the 1000 Genomes reference, we identified the group
of "to-be-determined" (tbd) for admixed individuals whose PCA information was not
matched with any of the five ancestries by definition. From each ancestry group, 1.3k
individuals were used as the validation datasets (See section entitled 'Simulated
data' in Methods). The SNP effect sizes from the discovery GWAS data were
adjusted using PRS-CS with the default parameters, fine-tuned, then combined using
the validation data based on 1.3k UKBB-based individuals per population and tested
in the rest of the UKBB-based individuals. The process of selecting causal SNPs,
assigning effect size, simulating phenotype data, and the downstream GWAS and
PRS analysis was repeated 20-fold.

We primarily focused on the PRS performance in the admixed testing sample.
DiscoDivas, which is based on PRS fine-tuned in AFR, EAS, EUR, and SAS, was
compared with the conventional PRS fine-tuned in the matched admixed validation
sample in scenarios of different causal SNP numbers, different discovery GWAS
sample sizes, and different causal SNP distribution across ancestry (See Figure 2)

254
Figure 2 Relative R² increase of DiscoDivas over the conventional PRS fine-tuned in a matched
sample when tested in admixed individuals. The x-axis shows the simulated number of causal
SNPs. The horizontal bar shows the mean relative R² increase and the color of the horizontal bar
indicates the *p*-value of the paired t-test of DiscoDivas PRS R² and conventional PRS R², with
cyan being *p*-value<0.0005, dark blue being *p*-value<0.05 and grey being *p*-value>0.05. In panels
a, b, and c, the causal SNP effect sizes are constant across different populations. The annotation
texts on the top of each panel shows the sample size of discovery GWAS of different
populations and the distribution of causal SNP effect sizes.

Although the comparison between DiscoDivas and the conventional method of fine-
tuning PRS with matched ancestry sample in a single test iteration usually showed
no statistical significance due to the small numeric differences, the paired t-test of
DiscoDivas R² and the conventional PRS R² over the 20 iterations better clarified
significant differences. When effect sizes of causal SNPs were constant across
different ancestries (Figure 2 panel a, b, and c), the PRS generated by DiscoDivas
had comparable accuracy with the PRS fine-tuned using matched data. We noticed
that when the sample size of non-European discovery GWAS dropped and the
dataset was relatively more Eurocentric, the advantage of DiscoDivas became less

statistically significant. In Figure 2 panel d, we compared DiscoDivas and the
conventional PRS method of fine-tuning the PRS with matched ancestry in the
scenario where causal SNPs were shared across all populations, but the effect sizes
varied linearly in the PCA space. The advantage of DiscoDivas over conventional
PRS method was more obvious in this scenario than when the effect sizes were
constant across populations (Figure 2 panel a and d), presumably because
personalized PRS combination with DiscoDivas better captured the changing effect
sizes for the admixed testing sample. In all the scenarios tested, the advantage of
DiscoDivas was least statistically significant when the number of causal SNPs was
10,000 but still significant when the number of causal SNPs was 1,000. Notably, the
accuracy of both DiscoDivas and the conventional PRS method was the lowest when
the number of causal SNPs was 10,000 (Supplementary Figure 1), indicating that the
difference of the two PRS methods became less obvious when the input data
became increasingly underpowered.
287
When predicting the individuals that are usually classified as single ancestries, i.e.
AFR, EAS, EUR, and SAS, DiscoDivas showed no statistically significant difference
or a slight advantage over the conventional PRS method (Supplementary Figure 2).
When predicting AMR individuals, we used admixed validation data (tbd) to fine-tune
the conventional PRS due to the small sample size of the AMR dataset. The PRS
performance when testing in the AMR dataset was similar as in admixed data but the
statistical significance was weaker, potentially due to the small sample size and the
high heterogeneity of the AMR dataset. In general, DisocDivas showed its clearest
advantage over the conventional method of fine-tuning PRS with matched PRS when
the testing data and the validation data for the conventional method were of different
ancestries.
299

Sensitivity tests

301   Since the quality of validation data is essential to the performance of DiscoDivas, we
302   evaluated the influence of minor missing information or alternative choices of
303   validation data with the following tests:
304
First, we considered the possible scenario where PRS weights for different
ancestries are provided from a publication but key detailed information about the
validation data was not fully available, especially the PCA information of the
validation datasets. A convenient approximation of the PCA of validation datasets is
the median PCA value of the 1000 Genome[28] individuals of a certain ancestry or
"superpopulation." Based on the simulation test as mentioned above, we tested the
influence of replacing the actual PCA of the UKBB validation datasets with the 1000
Genome approximate on the 1) PCA Euclidean distance, 2) combination coefficient
for interpolation, and 3) the PCA accuracy.
314
Since the UKBB individuals were selected to be included in validation datasets based
on the PCA information of the 1000 Genomes, the PCA distribution of UKBB
validation datasets closely aligned with that of the 1000 Genomes reference
(Supplementary Figure 3). PCA distances between the testing individuals and the
median point of validation datasets based on the actual UKBB validation data were
highly correlated with the PCA distances based on the 1000 Genome approximation
for all the testing ancestry groups AFR, AMR, EAS, EUR, SAS, and admixed ("tbd"),
with the data residing within the highly overlapped intervals and the correlation of
individual datapoints close to 1 (Supplementary Figure 4). The combination

coefficients were calculated assuming that the PRS weights fine-tuned in the four
validation datasets, i.e. AFR, EAS, EUR, and SAS, were of equal quality. According
to the formula in Method session, $w_{i,k}$, the combination coefficient of weighting the

PRS fine-tuned in validation sample k for individual i , should be $w_{i,k} \equiv \frac{1}{D_{i-k}} d_k$,

with the D_{i-k} being the PCA distance between individual i and the median point of
sample k; d_k being the adjustment coefficient for PRS fine-tuned in sample k based
on the distance between the validation samples. $w_{i,k}$ was compared between the two
scenarios of using the actual UKBB validation datasets versus using the 1000
Genomes approximate. The correlation of the combination coefficients was lower
than the correlation of the PCA distance, especially for SAS testing individuals.
However, each combination coefficient remained in almost the same range and the
PRS fine-tuned in the SAS sample still had the highest weights (Supplementary
Figure 5). When testing with the simulated data, the PRS R^2 had almost identical
distribution and correlation > 0.99 with the R^2 of PRS based on the actual PCA
information in all the simulated scenarios including when the causal SNP effect size
varied with the ancestries (Supplementary Figure 6). The high similarity of the PRS
accuracy despite the difference in combination coefficient might partly result from the
correlation of the PRS fine-tuned in different samples and the constant combination
coefficient range.
343
In addition, we tested if the results of DiscoDivas would remain robust for admixed
individuals when using a different set of validation datasets. In addition to the primary
simulation test where the validation datasets were simulated data based on UKBB
genotype, PRS were fine-tuned with the left-out simulated datasets that were
independent from the discovery GWAS while other parts of the analysis pipeline
remained the same. The simulated AMR dataset was used to fine-tune PRS for AMR
and admixed (tbd) testing samples for the conventional method. The PRS R^2 based
on the two sets of validation datasets were compared in the scenarios where the
discovery GWAS was based on 100k AFR, EAS, EUR, and SAS, and where the
causal SNP effect sizes were constant across different ancestries. The correlation of
PRS R^2 based on UKBB-based validation datasets and purely simulated validation
datasets of DiscoDivase was larger than 0.99 in at scenarios, much higher than that
of conventional PRS method, which ranged from 0.73 to 0.98 (Supplementary Figure
7). The advantage of DiscoDivas over the conventional PRS method showed a
similar pattern (Supplementary Figure 8)
359

Biobank data results

We downloaded publicly available summary statistical data of body-mass index
(BMI), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol
(LDL), total cholesterol (TC), triglycerides (TG), systolic blood pressure (SBP),
diastolic blood pressure (DBP), coronary artery disease (CAD), and diabetes mellitus
(DM2) and adjusted the SNP effect size using LDpred2 as described previously[5].
366
For the quantitative traits, we used the validation samples of AFR, EAS, EUR, SAS,
and admixed ("tbd") ancestry to fine-tune the model. The remaining UKBB samples
were used as the testing data. The results for empiric quantitative trait data were
highly aligned with the simulation results (Figure 4): DiscoDivas showed a robust
advantage over the conventional PRS method of fine-tuning PRS with matched or
similar ancestry samples when compared across the 7 traits in the admixed testing
dataset. When predicting AFR, EAS, EUR, and SAS, DiscoDivas and the
conventional PRS method had similar performance. The results of both methods in

AMR testing dataset had large deviations due to the small sample size and greater
genetic heterogeneity of the AMR data.

377
378
Figure 3 Relative R² increase of DiscoDivas over the conventional PRS fine-tuned in a matched
sample. The x-axis shows the population in which the PRS was tested. We used "tbd" as the
fine-tuning dataset for the test in both tbd and AMR due to the absence of matched AMR
validation data. The horizontal bar shows the mean of relative increase and the line-type of the
bar indicates the *p*-value of paired t-test of DiscoDivas PRS R² and conventional PRS R², with the
solid bar being *p*-value <0.05 and dotted bar being *p*-value>0.05

For the binary traits coronary artery disease (CAD) and type 2 diabetes (DM2)
(Figure 4), we used the AFR, EAS, EUR, SAS, AMR, and OTH (i.e., unclassified)
samples from AoU as the fine-tuning data and tested in AFR, EAS, EUR, SAS, and
tbd individuals in UKBB and AFR, EAS, EUR, SAS, and AMR individuals in MGBB.
The DiscoDivas PRS were based on the PRS fine-tuned in AFR, EAS, EUR, and
SAS and used the default assumption that the PRS fine-tuned from all the samples
were of similar quality even though the sample sizes of both discovery GWAS and
the fine-tuning samples were not balanced across different ancestries. AMR in UKBB
was excluded because of the small sample size (N=669).
394
The PRS fine-tuned in different single samples and the DiscoDivas PRS had similar
performances. It also appeared that some of the validation sample could be
underpowered: generally, we expect the PRS fine-tuned in the matched sample to
perform the best in the testing samples, but PRS fine-tuned in larger validation data
performed better than PRS fine-tuned in smaller validation data in general. For
example, the PRS fine-tuned in EAS AoU data performed worse than other PRS in
both MGBB and UKBB EAS data and had low accuracy in other testing data as well;
the CAD PRS fine-tuned in EUR performed better than all the other PRS in all the
testing data and the effective sample size of EUR CAD validation data was much
larger than all the other validation data.

406
407
408 **Figure 4 PRS performance for coronary artery disease (CAD) and type 2 diabetes (DM2) tested in**
409 **UKBB and MGBB. The plot shows OR per SD with the error bar showing 95% CI. The sub-panels**
410 **show that population of the testing sample and the different colors show the method for**
411 **generating the PRS, either fine-tuning in a single sample or combining the PRS using**
412 **DiscoDivas.**

Discussion

We propose a new method, DiscoDivas, to interpolate the PRS for diverse, especially
admixed, ancestries with a generalized framework that does not requiring binning
into discrete ancestries. Our results shows that the accuracy of DiscoDivas was
comparable to or greater than the conventional method, i.e. fine-tuning using the
matched population sample when available. In addition, when generating PRS for a
wide range of ancestries, DiscoDivas did not require shifting from several sets of
PRS weight fine-tuned in discrete samples while remaining matched with the
ancestry information. Our method provides a new solution to generate PRS for
underrepresented, generally admixed, populations and as well as generate a
harmonized PRS model across different ancestries.

The performance of our method depends on the quality of both the discovery GWAS
data and the validation data. As shown in the simulation test, discovery GWAS
datasets that represent diverse ancestries with sufficient sample size will increase
the accuracy of interpolated PRS generated by DiscoDivas. On the contrary,
Eurocentric and underpowered discovery GWAS datasets would limit the advantage
of DiscoDivas over the conventional PRS method. This might partly explain the
limited advantage of DiscoDivas when predicting binary traits: the discovery GWAS
datasets were highly Eurocentric and the GWAS, especially the non-European ones,
could be more underpowered than quantitative trait GWAS. Furthermore, the PRS
fine-tuned in validation datasets of insufficient sample size will be overfitted and
cannot be used to fairly evaluate the performance of either the conventional PRS
method or DiscoDivas. We aimed to address this issue by only using traits that 1)
had effective sample sizes larger than 200 in all the validation samples, and 2) had
high-quality phenotyping data in both the validation datasets and the testing datasets,
However, Asian populations were largely under-represented in the current public
biobanks: the effective sample size of many binary traits in EAS or SAS can be as
small as <200 even in AoU, the most diverse and large-scale largely publicly-
available biobank we had access to. This limited our choice for binary traits to only
CAD and DM2. One additional limitation of our method is that DisoDivas does not
consider the local ancestry information, which improve PRS predictions in various
research[24,29,30], especially PRS prediction of newly admixed populations[31].

Our research underscores the notion that non-European populations, both admixed
and singe-ancestry populations, remain largely under-represented in the existing
genetic data. Furthermore, some potential extensions of our method will not become
possible until we collect more diverse and larger datasets. First, our method has not
been designed nor tested for extrapolating data, e.g. generating PRS for continental
African samples based on African American, European, and Asian samples. Even
though it is mathematically plausible to alter our method to extrapolate the PRS, we
lack data such as continental African samples to test the method. Secondly, we
currently only consider the assumption that the most informative genome-wide PRS
weight shifts linearly in the PCA space. Although more complicated PRS
interpolation, e.g. interpolation guided by local ancestry information [24,29,30], pathway-
specific[32,33] and annotation-guided[34] PRS weights and polynomial interpolation[35,36],
can possibly further improve the PRS accuracy, training such complicated models
would require collecting much larger and more diverse datasets than the existing
data. Finally, additional biological insights could be revealed by interpolating PRS if
genetic data of all the involved diverse ancestries are of sufficient power. In this case,

the differences between interpolated PRS and the PRS trained using the matched ancestry would indicate the population- or sample- specific factors absent in the interpolation model, e.g. population-specific genetic variance[37], complicated population stratification involving cofounding factors[38,39], sample/ancestry-specific modifiers like local adaptation[38], gene x environment interactions[40] or other factors that contribute to the genetic variant frequency or effect size in these samples/ancestries.

In conclusion, our method provides a new option to treat the ancestry information as a continuous variable and interpolate a harmonized PRS for diverse ancestries. Notably, although our method was developed primarily to calculate PRS when the matched validation datasets were unavailable, our research showed that successfully interpolating PRS required sufficient input data and highlighted the need to collect genetic data for underrepresented populations. We believe that more diverse and larger data collected in the coming future will enable the development of new methods of interpolating PRS and the elucidation of the genetic basis of complex traits.

Methods

DiscoDivas

DiscoDivas interpolates PRS of testing individuals of diverse ancestry according to the testing individual's PRS calculated using the PRS weight fine-tuned in other validation datasets and genetic distance information. The pipeline consists of two parts: harmonizing the input PRS data and interpolating the PRS.

Data harmonization
To reduce the bias in the interpolation, the PRS and PCA information should be in a unified and harmonized scale. First, all the individuals in the validation datasets and the testing dataset are projected in the same PCA space based on balanced reference data covering the global genetic ancestry continuum. The reference data is essential to avoid a skewed correlation between the similarity of the genotype and the genetic distance and ensure that the PCA Euclidian distance can present consistent genetic distance. The results presented in this study were based on PCA calculated using pruned SNPs of 1000 Genomes[28] samples. A detailed description of calculating PCA and Euclidian distance in this research is provided in the section entitled 'Calculation of 1000 Genomes-based PCA and Euclidean distance.'

Second, all the PRS input should be transferred to a comparable scale. We regressed out the top 10 PCs from the PRS and then standardized the PRS residuals to mean = 0 and standard deviation =1.

PRS interpolation
The overall mathematical model of DiscoDivas is a linear combination of PRS based on the weight fine-tuned in different validation datasets:

$$PRS_i = \sum a_i \, w_{i,k} PRS_{i,k}$$

509　where $PRS_{i,k}$ is the normalized PRS of individual *i* trained in validation dataset *k*; $w_{i,k}$
510　is the combination weight which is a function of genetic distance between the
511　individual *i* and dataset *k* and other factors. a_i is a constant for individual *i* so that
512　$\sum a_i\, w_{i,k} = 1$.
513

514　The essential factor contributing to $w_{i,k}$ is the reciprocal of D_{i-k} , the genetic distance
515　between individual *I* and dataset *k*, so that the interpolation is basically linear. In the
516　ideal situation where all the validation samples are independent and generate PRS of
517　the same level of accuracy, the genetic distance between the testing individuals and
518　validation datasets is the only contribution factor and we define:

519
$$w_{i,k} \equiv \frac{1}{D_{i-k}}.$$

520　However, considering the more realistic scenarios where the validation samples can
521　be correlated and the PRS trained from different validation datasets can be of
522　different accuracy, we introduce two parameters:
　　　　1) d_k: tuning parameters based on the genetic distance / correlation between
523
524　　　　　the training datasets.
525　　　　2) r_k: tuning parameter that represent the accuracy of the PRS fine-tuned in
526　　　　　sample *k*;
527　so that the overall combination weight is

528
$$w_{i,k} \equiv \frac{1}{D_{i-k}}\, d_k\, r_k$$

529　The final model of DiscoDivas is

530
$$PRS_i = \sum a_i\, \frac{1}{D_{i-k}}\, d_k\, r_k\, PRS_{i,k}$$

Here we propose the default method for calculating d_k and r_k:
d_k is based on the genetic distance matrix G in which each row and column
represent a validation sample, and the element is genetic distance between the
samples, with diagonal ones being zero. The shrinkage follows the similar principle of
correcting marginal SNP effect size by inversing the LD matrix, except that the
correlation between the shrinkage in this step d_k and other factors like the genetic
distance between individuals in the testing data and the validation sample D_{i-k} and
the accuracy of the PRS fine-tuned in the validation sample, the vector of shrinkage
parameter d_k is only derived from G^{-1}:

541
$$\vec{d} = G^{-1}\vec{1}$$

, where $\vec{1}$ is a vector of the same length as $\vec{d}$ and with all the elements being 1.
r_k is based on the accuracy of the PRS fine-tuned in the sample k. Theoretically, a
PRS based on common SNPs can explain all the heritability contributed by common
SNPs under the additive assumption. Under this scenario, the PRS R^2 is close to the
heritability h^2, and the PRS is saturated (namely, adding more samples in the
Discovery GWAS would further increase the PRS accuracy if other conditions remain
the same). Previous research used percentage of heritability explained to present the
accuracy of the PRS so that PRS predicting traits of different heritability and binary
traits of different prevalence can be compared directly. Here we recommend using
common SNP heritability explained as the first choice of r_k if the heritability of the
target trait in the validation samples or a larger sample but is homogenous with the
validation sample is available:

554
$$r_k = \sqrt{\frac{R^2_{PRS}}{h^2}}$$

555　If h^2 is unknown, we provided an alternative approach that approximates the PRS

556 given the fact that most of the PRS is far from saturation and the accuracy of the
557 PRS is roughly linearly correlated with the sample size of the discovery GWAS N_k,
558 we combine the information from different samples in a similar way by combining Z
559 scores in fixed-effect size meta-analysis:

$$r_k = \sqrt{N_{k\ discovery}}$$

561 If the trait used in the discovery GWAS is not the same for all the validation data, the
562 accuracy of the PRS for predicting the target traits also depends on the heritability of
563 the trait in the discovery GWAS $h_{k\ discovery}{}^2$ and the genetic correlation between the
564 discovery GWAS trait and the target trait $rg_{k\ discovery-target}$

$$r_k = \sqrt{N_{k\ discovery} * h_{k\ discovery}{}^2 * rg_{k\ discovery-target}}$$

In a common scenario where discovery data come from multiple GWAS from
different ancestries and of decent statistical power for each ancestry yet the
heritability of the target trait in the validation sample is unknown or cannot be
accurately estimated, the accuracy of the PRS fine-tuned in each single-ancestry
validation sample is hard to estimate but is likely of similar accuracy. Therefore r_k
can be omitted, or equivalently set to a default constant value of 1.
572
573 In the DiscoDivas script provided, the r_k is set to be the default value 1 unless
574 defined by the user otherwise, a_i, D_{i-k}, d_k is automatically calculated from the PCA
575 information provided by the user.
576

Constructing PRS with single fine-tuning sample

The PRS were derived from multiple GWAS conducted in different populations.
GWAS data were first processed with PRS-CS or LDpreds2 to generate adjusted
SNP weight: Hapmap3 SNP were first extracted from each GWAS as the input for
the PRS method. The PRS methods were performed using default parameters: For
PRS-CS, parameters of the prior distribution were set to phi = 1, 10^{-2}, 10^{-4}, 10^{-6}, a =
1, b = 0.5 and the parameters of Markov Chain Monte Carlo (MCMC) were total
number of MCMC iterations = 1000, number of burn-in = 500, thinning factor of the
Markov chain = 5. For LDpred2, the parameter were the default set as in previous
research[5]: proportion of variants assumed to be causal was 1.0×10^{-4}, 1.8×10^{-4},
3.2×10^{-4}, 5.6×10^{-4}, 1.0×10^{-3}, 1.8×10^{-3}, 3.2×10^{-3}, 5.6×10^{-3}, 1.0×10^{-2},
1.8×10^{-2}, 3.2×10^{-2}, 5.6×10^{-2}, 1.0×10^{-1}, 1.8×10^{-1}, 3.2×10^{-1}, 5.6×10^{-1} and 1, the
scale of heritability was 0.7, 1 and 1.4 times of the estimated heritability, with options
of whether allowing a sparse output or not.
591
Each set of parameters generated a corresponding set of adjusted SNP weight,
which were then used to calculate PRS in the fine-tuning samples. The most
predictive PRS for each GWAS was selected based on a linear or logistic regression
model predicting the phenotype using the PRS and adjusting for top 10 PCs, age,
sex information and genotyping batch for biobank empirical analyses, and adjusting
for only top 10 PCs for simulated analyses. For All of Us data, sex information
combined assigned sex and self-reported gender to capture inclusiveness in data
collection.
600
601 To generate the final PRS weight, multiple top-performing PRS based on each
602 GWAS were combined through a linear or logistic regression in the fine-tuning
603 sample. Final adjusted PRS weights were a linear combination of the top SNP
604 weights from each GWAS, weighted by the regression coefficients. These combined

605   SNP weights were subsequently used to calculate PRS in the testing sample.
606

607   Conventionally, when fine-tuning polygenic risk scores (PRS) for a testing sample, it
608   is ideal to use a sample from a matched or similar population. If such a sample is
609   unavailable, the PRS can be fine-tuned using any available sample, which is often
610   from individuals of European ancestry.
611

612 Calculation of 1000 Genomes-based PCA and Euclidean

613 distance

We use 1000 Genomes as the reference panel for PCA calculation. The PCA should
be based on SNPs that are constantly included in as many samples as possible to
enable the use of wide-ranging training and validation datasets. We started with the
Hapmap3 SNPs for this set of SNPs, which has been widely used as a subset of
SNPs that approximates the feature of genome-wide common SNPs in many recent
studies that involve multi-ancestry prediction [6,25,26,41]. We further filtered for the SNPs
likely to be frequently genotyped or imputed with relatively high quality by most
samples based on the 1000 Genome data: Hapmap3 SNPs were first extracted from
the five super-populations, Africans (AFR), Admixed Americans (AMR), East Asians
(EAS), Europeans (EUR) and South Asians (SAS) of the 1000 Genomes. Secondly,
SNPs described as the following were excluded: 1) of minor allele frequency lower
than 1% in any of the super-population, 2) of minor allele frequency lower than 5% in
the combined 1000 Genomes data, and 3) in the long-range LD region (25Mb –
35Mb by hg19 assembly on chromosome 6 and 7Mb – 13Mb on chromosome 8). To
calculating the PCA loading, the QC'ed SNPs of the five super-populations were
merged then pruned using the PLINK2 function "indep-pairwise" with the parameter
"200 100 0.1" - namely the pruning was performed using window size = 200kb, step
size = 100, and phased-hardcall-r^2= 0.1. The principal components and the SNP
loadings are calculated using PLINK2 function "pca" with the parameter "allele-wts"
based on the pruned SNPs.
634

Based on the protocol suggested on the PLINK2 website (https://www.cog-
genomics.org/plink/2.0/score#pca_project), we projected samples for fine-tuning and
PRS testing into the PCA space as describe above by calculation the linear score,
i.e. the sum of alternative alleles weighted by the SNP effect size, using the PLINK2
function "score" with the SNP loadings as effect size. The original online protocol
suggested linear score should be first scaled to standard variation and then rescaled
by multiplying the square root of eigenvalue. However, the actual standard deviation
of a sample in the same PCA space varies with the homogeneity and the ancestry of
the sample. Forcing the PCA of all the samples to have the same standard deviation
will cause inconsistent scaling when the samples can be of different ancestries.
Therefore, we directly calculated the PCA from sum basic linear score based on the
SNP loadings as generated above without any further scaling. The PCA in this study
was the sum basic linear score calculated using the PLINK2 function "score" with the
parameter "cols=+scoresums'". For large samples whose genotype data were divided
into per-chromosome files, the same commands were used to calculate per-
chromosome score and the genome-wide score was the sum of the score of all the
autosomes.
652

653   In DiscoDivas' default setting, the genetic distance between two individuals is defined
654   as the Euclidian distance between the PCA of the two individuals. When the genetic

655 distance calculation involves a sample, we use the median point to present the whole
656 sample.
657
658 We also explored the relationship between number of PCs included in the calculation
659 and the Euclidean distance calculated (Supplementary Figure 9) and the distance
660 calculated converged when the number of PCs was larger than 6 in our tests. In our
661 analysis we use the top 10 PCs to calculate the PCs.
662

Genetic ancestry reference

We noticed that the protocol of generating top PCs for ancestry references varied in
previous publications. In our pilot test (see supplementary text section entitled 'Pilot
test of generating PCA based on less QC'ed SNPs'), we compared the ancestry
reference based on Hapmap3 SNP without any QC and found the result to be highly
correlated. We used the same set of PCs based on QC'ed SNP as described in
section 'Calculation of 1000 Genomes-based PCA and Euclidean distance' for both
genetic ancestry reference and Euclidean distance calculation for data consistency.
671
Random forest model of 100 trees was trained based on the 1000 Genome data. The
out-of-bag estimate of error rate stabilize at the level of 0.28% after the number of
PCs passed 5. We used the model using the top 6 PCs to infer the genetic ancestry
of UK Biobank individuals and the Mass General Brigham Biobank individuals. The
genetic ancestry of an individual was assigned to any of the five ancestries
represented in the 1000 Genomes reference data, i.e. AFR, AMR, EAS, EUR and
SAS, if the highest probability of an individual belonging to that ancestry passed a
threshold. If none of the ancestries had a probability above the threshold, the
individuals were assigned as "to be decided" (tbd), which indicated that the individual
was of admixed ancestries. With the consideration of the sample size and confirmed
by visual inspection, the threshold of probability for UK Biobank and the Mass
General Brigham Biobank was 0.9 and 0.8 respectively.
684

Data

UK Biobank
The UK Biobank (UKBB) is a volunteer sample of approximately 500,000 adults aged
40-69 upon enrollment living in the United Kingdom recruited since 2006[42]. UKBB
data used in this research were first QC'ed with the following process: Remove the
individuals meeting the criteria that indicate low genotype quality or contamination: 1)
have missing genotype rate larger than 0.02; 2) have genotype-phenotype sex
discordance; 3) are identified as having excess heterozygosity and missing rates; 4)
are identified as putatively carrying sex chromosome configurations that are not
either XX or XY; 5) appeared to have unreasonably large numbers of relatives. From
the remaining samples, individuals from a group of multiple individuals that are closer
than 3rd-degree relatives were retained. 415,402 individuals were left after the QC.
390,037 were self-identified as EUR, 7,039 AFR, 8,652 non-Chinese Asian (ASN),
1430 Chinese (CHN) and 6572 unknown or not answered ("tbd"), and 1672 as
admixed (MIX). The genetic ancestry referred from PC was largely correlated with
the self-reported race, with 385,038 EUR, 7,450 AFR, 8,298 SAS, 2,163 EAS, 669
AMR and 11,784 admixed, or to-be-decided ("tbd").
702

In the PRS test, UKBB samples were grouped by their genetic ancestry (see section
'Genetic ancestry reference'). The validation datasets for the single-ancestry
populations (AFR, EAS, EUR and SAS) were based on 1.3k randomly selected
samples whose self-report ancestry matched with their genetic ancestry and the
probability of random forest = 1. The validation dataset for admixed ancestry ("tbd") is
1.3k randomly selected samples of individuals of "tbd" genetic ancestry (see
Supplementary Figure 3). AMR didn't have its corresponding validation dataset due
to its small sample size and we used "tbd" validation datasets as a proxy since the
two genetic ancestries had similar PCA. The remaining individuals of UKBB were
used as testing data.

713
The quantitative trait of the UKBB samples was the measurement collected after the
participants enrolled. The lipid trait measurement was adjusted for cholesterol-
lowering medication by dividing TC by 0.8 and LDL by 0.7 as before[43]. Cases of
coronary artery diseases (CAD) are defined using the definition described
previously[24]; Cases of diabetes are defined as ever report the following code: E10X,
E11X, E12X, E13X, and E14X where X can be any integer between 0 to 9 in the
ICD10 diagnosis code.

721
722 UKBB participants provided consent in accordance with the primary IRB protocol,
723 and the Massachusetts General Hospital IRB approved the present secondary data
724 analysis of the UKBB data under UKBB application 7089.

725
Mass General Brigham Biobank
The Mass General Brigham Biobank (MGBB) is a volunteer sample of approximately
142,000 participants receiving medical care in the Mass General Brigham health care
system recruited starting 2010. 53,306 MGBB participants underwent genotyping via
Illumina Global Screening Array (Illumina, CA). MGBB genotype data was quality
controlled, imputed and assigned one of the populations AFR, AMR, EAS, EUR, SAS
using K-nearest neighbor model as described previously[44]. The phenotype data of
CAD and diabetes are drawn from PheCodes based on International Classification of
Diseases codes, Nineth (ICD9)110 and Tenth (ICD10) revisions, from the EHR as
described previously[32]. MGBB participants provided consent in accordance with the
primary IRB protocol, and the Massachusetts General Hospital IRB approved the
present secondary data analysis.

738
All of Us Research Program
The *All of Us* (AoU) Research Program is a volunteer sample of more than one
million United States residents recruited starting 2016. AoU aims to engage
communities previously underrepresented in biomedical research in the United
States and beyond[45]. In the present analysis, genetic data from the v7 245,394
participants who were genotyped using short read whole genome sequencing
(srWGS) data. Hapmap3 SNPs were extracted for the callset with the threshold of
(AF) > 1% or population-specific allele count (AC) > 100. Related individuals were
pruned according to the information provided by AoU. Due to the inclusive data
collection, we didn't excluded individuals whose self-report gender were different with
their assigned sex at birth and used the combination of self-report gender and
assigned sex as one of the covariates. The predicted ancestry information was
provided by AoU[46]. The phenotypes were defined as described in previous research
by Buu *et al*[47].
753

Simulated data

To generate the simulated GWAS summary statistics, the genotype data was generated by Zhang et al[6] and downloaded from https://dataverse.harvard.edu/dataverse/multiancestry. Only Hapmap3 SNPs were included in the simulation. Causal SNPs were randomly selected from the Hapmap3 SNPs and simulated per allele effect size following normal distribution. The ladder of causal SNP number was 100, 1000, 3000, 10000 and the heritability in each of the population was 0.6.

When simulated trait whose causal SNP effect size varied linearly in the PCA space, we first assumed that individuals whose PCA was the median point of the 1000 Genomes followed multivariate normal distribution with the covariance matrix being:

	EUR	SAS and EAS	AFR
EUR	1	0.7	0.4
SAS and EAS	0.7	1	0.7
AFR	0.4	0.7	1

Similar to the principle that PRS weight can be interpolated is equivalent to PRS can be interpolated, causal SNP effect size varies linearly in the PCA space and, therefore, can be interpolated is equivalent to genetic burden can be interpolated. The genetic burden of an individual is the weighted sum of what the genetic burden could be based on the simulated SNP effect size of the median point of each validation sample, with the weight proportion to the reciprocal of the PCA distance. We assumed that the non-genetic factor of individuals across different ancestries could be summed up as a quantitative variable independently drawn from the same normal distribution. The phenotype is the sum of genetic burden and non-genetic factor:

$$phenotype_i = \sum \beta_j x_{j,i} + E_i$$

where the $phenotype_i$ and E_i were the phenotype and non-genetic factor of individual i; β_j was the effect size of causal SNP j, and $x_{j,i}$ was the number of risk alleles of individual i in SNP j.

We used the PLINK2[28] to calculate the genetic burden based on the simulated causal SNPs and effect size and used R to simulate the non-genetic factors, scale the genetic burden and non-genetic factor, and generate a phenotype of heritability set to be 0.6. We used up to 100k individuals per population to generate the summary statistical GWAS as the discovery data for the PRS test. The rest simulated data were left out for the validation and testing datasets

In addition to the completely simulated data, we generated more realistic validation and testing datasets of a wider ancestry range by using the QC'ed genotype data from UKBB described in the section 'Biobank data.' While we used all the non-European testing data, the EUR testing dataset was down-sampled to 10,000 for the simulation test to reduce the computation burden. We simulated the genetic burden, non-genetic factor, and phenotype based on the real-life UKBB genotype data with the same pipeline and parameters. The simulated data based on UKBB genotype data were used as validation and testing data in the main test and left-out completely simulated data were used in the sensitivity test.

Acknowledgement

We thank the participants and staff of the UK Biobank (application 7089), Mass General Brigham Biobank, and *All of Us* Research Program. We thank Ying Wang, Paul O'Reilly, Raymond Walters for helpful discussion and advice.

Data and Code availability

The access to biobank data (UK Biobank, Mass General Brigham Biobank, and All of US Research Program) were gained upon application. The simulated genotype data based on 1000 Genomes were downloaded from https://dataverse.harvard.edu/dataset.xhtml?persistentId=doi:10.7910/DVN/COXHAP ; The resource of summary statistics GWAS data used to generate PRS were given in the supplementary file. The scripts of running DiscoDivas and other supporting files can be found at https://github.com/YunfengRuan/DiscoDivas

Reference

1. Martin, A. R. *et al.* Clinical use of current polygenic risk scores may exacerbate health disparities. *Nat Genet* **51**, 584–591 (2019).
2. Miao, J. *et al.* Quantifying portable genetic effects and improving cross-ancestry genetic prediction with GWAS summary statistics. *Nat Commun* **14**, 832 (2023).
3. Ruan, Y. *et al.* Improving polygenic prediction in ancestrally diverse populations. *Nat Genet* **54**, 573–580 (2022).
4. Jin, J. *et al.* MUSSEL: Enhanced Bayesian Polygenic Risk Prediction Leveraging Information across Multiple Ancestry Groups. *bioRxiv* 2023.04.12.536510 (2023) doi:10.1101/2023.04.12.536510.
5. Patel, A. P. *et al.* A multi-ancestry polygenic risk score improves risk prediction for coronary artery disease. *Nat Med* **29**, 1793–1803 (2023).
6. Zhang, H. *et al.* A new method for multiancestry polygenic prediction improves performance across diverse populations. *Nat Genet* **55**, 1757–1768 (2023).
7. Ding, Y. *et al.* Polygenic scoring accuracy varies across the genetic ancestry continuum. *Nature* **618**, 774–781 (2023).
8. Landry, L. G., Ali, N., Williams, D. R., Rehm, H. L. & Bonham, V. L. Lack Of Diversity In Genomic Databases Is A Barrier To Translating Precision Medicine Research Into Practice. *Health Aff* **37**, 780–785 (2018).
9. The All of Us Research Program Genomics Investigators. Genomic data in the All of Us Research Program. *Nature* **627**, 340–346 (2024).
10. Fatumo, S. *et al.* Polygenic risk scores for disease risk prediction in Africa: current challenges and future directions. *Genome Medicine* vol. 15 Preprint at https://doi.org/10.1186/s13073-023-01245-9 (2023).
11. Dokuru, D. R., Horwitz, T. B., Freis, S. M., Stallings, M. C. & Ehringer, M. A. South Asia: The Missing Diverse in Diversity. *Behav Genet* **54**, 51–62 (2024).
12. Stefflova, K. *et al.* Dissecting the Within-Africa ancestry of populations of African descent in the Americas. *PLoS One* **6**, (2011).

13.   Harlemon, M. *et al.* A custom genotyping array reveals population-level
heterogeneity for the genetic risks of prostate cancer and other cancers in
Africa. *Cancer Res* **80**, 2956–2966 (2020).

14.   Anagnostou, P. *et al.* Inter-individual genomic heterogeneity within European
population isolates. *PLoS One* **14**, (2019).

15.   Pan, Z. & Xu, S. Population genomics of East Asian ethnic groups. *Hereditas*
vol. 157 Preprint at https://doi.org/10.1186/s41065-020-00162-w (2020).

16.   Khera, A. V *et al.* Whole-Genome Sequencing to Characterize Monogenic and
Polygenic Contributions in Patients Hospitalized With Early-Onset Myocardial
Infarction. *Circulation* **139**, 1593–1602 (2019).

17.   Duncan, L. *et al.* Analysis of polygenic risk score usage and performance in
diverse human populations. *Nat Commun* **10**, 3328 (2019).

18.   Wang, M. *et al.* Validation of a Genome-Wide Polygenic Score for Coronary
Artery Disease in South Asians. *J Am Coll Cardiol* **76**, 703–714 (2020).

19.   Ge, T. *et al.* Development and validation of a trans-ancestry polygenic risk
score for type 2 diabetes in diverse populations. *Genome Med* **14**, 70 (2022).

20.   O'Sullivan, J. W. *et al.* Polygenic Risk Scores for Cardiovascular Disease: A
Scientific Statement From the American Heart Association. *Circulation* vol. 146
E93–E118 Preprint at https://doi.org/10.1161/CIR.0000000000001077 (2022).

21.   Lewis, C. M. & Vassos, E. Polygenic risk scores: From research tools to
clinical instruments. *Genome Medicine* vol. 12 Preprint at
https://doi.org/10.1186/s13073-020-00742-5 (2020).

22.   Xiang, R. *et al.* Recent advances in polygenic scores: translation, equitability,
methods and FAIR tools. *Genome Medicine* vol. 16 Preprint at
https://doi.org/10.1186/s13073-024-01304-9 (2024).

23.   Truong, B. *et al.* Integrative polygenic risk score improves the prediction
accuracy of complex traits and diseases. *Cell Genomics* **4**, (2024).

24.   Wang, Y. *et al.* Polygenic prediction across populations is influenced by
ancestry, genetic architecture, and methodology. *Cell Genomics* **3**, (2023).

25.   Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A. & Smoller, J. W. Polygenic
prediction via Bayesian regression and continuous shrinkage priors. *Nat*
Commun **10**, 1776 (2019).

26.   Privé, F., Arbel, J. & Vilhjálmsson, B. J. LDpred2: better, faster, stronger.
Bioinformatics **36**, 5424–5431 (2021).

27.   Chang, C. C. *et al.* Second-generation PLINK: Rising to the challenge of larger
and richer datasets. *Gigascience* **4**, (2015).

28.   Auton, A. *et al.* A global reference for human genetic variation. *Nature* **526**,
68–74 (2015).

29.   Atkinson, E. G. *et al.* Tractor uses local ancestry to enable the inclusion of
admixed individuals in GWAS and to boost power. *Nat Genet* **53**, 195–204
(2021).

30.   Sun, Q. *et al.* Improving polygenic risk prediction in admixed populations by
explicitly modeling ancestral-differential effects via GAUDI. *Nat Commun* **15**,
(2024).

31.   Marnetto, D. *et al.* Ancestry deconvolution and partial polygenic score can
improve susceptibility predictions in recently admixed individuals. *Nat*
Commun **11**, (2020).

32.   Xu, Y. *et al.* Effect of Pathway-Specific Polygenic Risk Scores for Alzheimer's
Disease (AD) on Rate of Change in Cognitive Function and AD-Related
Biomarkers Among Asymptomatic Individuals. *Journal of Alzheimer's Disease*
94, 1587–1605 (2023).

33.   Tubbs, J. D. *et al.* Pathway-Specific Polygenic Scores Improve Cross-Ancestry
Prediction of Psychosis and Clinical Outcomes. Preprint at

https://doi.org/10.1101/2023.09.01.23294957 (2023).

34. Miao, J. *et al.* Quantifying portable genetic effects and improving cross-
ancestry genetic prediction with GWAS summary statistics. *Nat Commun* **14**,
(2023).

35. Kumar, R., Bhattacharya, S. & Murmu, G. Exploring Optimality of Piecewise
Polynomial Interpolation Functions for Lung Field Modeling in 2D Chest X-Ray
Images. *Front Phys* **9**, (2021).

36. Womersley, R. S. & Sloan, I. H. *How Good Can Polynomial Interpolation on
the Sphere Be? Advances in Computational Mathematics* vol. 14 (2001).

37. Choudhury, A. *et al.* Population-specific common SNPs reflect demographic
histories and highlight regions of genomic plasticity with functional relevance.
BMC Genomics **15**, (2014).

38. Rees, J. S., Castellano, S. & Andrés, A. M. The Genomics of Human Local
Adaptation. *Trends in Genetics* vol. 36 415–428 Preprint at
https://doi.org/10.1016/j.tig.2020.03.006 (2020).

39. Mas-Sandoval, A., Mathieson, S. & Fumagalli, M. The genomic footprint of
social stratification in admixing American populations. **12**, 84429 (2023).

40. Patel, R. A. *et al.* Genetic interactions drive heterogeneity in causal variant
effect sizes for gene expression and complex traits. *Am J Hum Genet* **109**,
1286–1297 (2022).

41. Yengo, L. *et al.* A saturated map of common genetic variants associated with
human height. *Nature* **610**, 704–712 (2022).

42. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and
genomic data. *Nature* **562**, 203–209 (2018).

43. Graham, S. E. *et al.* The power of genetic diversity in genome-wide
association studies of lipids. *Nature* **600**, 675–679 (2021).

44. Koyama, S. *et al.* Decoding Genetics, Ancestry, and Geospatial Context for
Precision Health. *medRxiv* (2023) doi:10.1101/2023.10.24.23297096.

45. Kathiresan, N. *et al.* Representation of Race and Ethnicity in the
Contemporary US Health Cohort All of Us Research Program. *JAMA Cardiol*
8, 859–864 (2023).

46. Bick, A. G. *et al.* Inherited causes of clonal haematopoiesis in 97,691 whole
genomes. *Nature* **586**, 763–768 (2020).

47. Truong, B. *et al.* Integrative polygenic risk score improves the prediction
accuracy of complex traits and diseases. *medRxiv* (2023)
doi:10.1101/2023.02.21.23286110.

Supplementary Figures

Supplementary Figure 1: Comparison of PRS R^2 of conventional PRS method and DiscoDivas when the validation dataset for the conventional method were of the matched ancestry with the testing dataset. The four subplots correspond to the four simulated scenarios of different discovery GWAS sample size and causal SNP effect size shown in the 4 panels in Figure 2. Within each subplot, each panel shows the performance of the two methods in each testing sample; the color of the datapoints showed the number of causal SNPs simulated.

AFR 0; EAS 40k; EUR 100k; SAS 0; Causal SNP effect size : Constant

AFR 100k; EAS 100k; EUR 100k; SAS 100k; Causal SNP effect size : Varying

Supplementary Figure 2: The relative increase PRS R^2 of DiscoDivas over
conventional PRS method. The four subplots correspond to the four simulated
scenarios of different discovery GWAS sample size and causal SNP effect size shown
in the 4 panels in Figure 2. Within each subplot, each panel shows the performance of
the two methods in each combination of validation sample for the conventional PRS
method and the testing sample; the horizontal bar show the mean value of the relative
increase; the color of the horizontal bar indicating mean value of relative increase and
p-value of the paired t-test of DiscoDivas PRS R^2 and conventional PRS R^2, with cyan
being the mean increase>0 and p-value<0.0005, dark blue being mean increase>0
and p-value<0.05, dark red being mean increase<0 and p-value<0.05, and grey being
p-value>0.05
958

962
963

967 Supplementary Figure 3: The comparison of PCA of UKBB validation sample and the
968 1000 Genomes reference.
969

973
974

Supplementary Figure 4: The comparison of PCA distance between the testing
individual and the median point of validation samples when using the actual value of
UKBB validation samples and the approximated value of using the 1000 Genomes
sample. Each column of the panels shows the ancestry of testing individuals, and each
row of the panels shows the distance to the validation samples. The range of the
distance to median point of the validation samples shows in the lower edge of the panel,
with the blue color indicating the range of distance based on actual UKBB validation
sample and the red color indicating the range of distance based on 1000 Genomes
approximate. The correlation of the two sets of calculated distance is shown in each
panel.

985
986

Supplementary Figure 5: The comparison of the interpolation combination coefficient
when using the actual value of UKBB validation samples and the approximated value
of using the 1000 Genomes sample. Each column of the panels shows the ancestry of
testing individuals, and each row of the panels shows validation sample for which the
interpolation combination coefficient is for. The range of interpolation combination
coefficients shows in the lower edge of the panel, with the blue color indicating the
range of combination coefficients based on actual UKBB validation sample and the red
color indicating the range of combination coefficients based on 1000 Genomes
approximate. The correlation of the two sets of combination coefficients is shown in
each panel.
997

998
999

Supplementary Figure 6: The comparison of DiscoDivas PRS R^2 when using the actual value of UKBB validation samples and the approximated value of using the 1000 Genomes sample. Each column of the panels shows the ancestry of testing individuals, and each row of the panels shows the simulated number of causal SNPs. The four subplots correspond to the four simulated scenarios of different discovery GWAS sample size and causal SNP effect size shown in the 4 panels in Figure 2.

Supplementary Figure 7 Comparison of PRS R^2 of using UKBB-based validation
sample and using the purely simulated validation sample. The upper subplot shows
the results of conventional PRS method and the lower shows the result of
DiscoDivase
Within each subplot, the column of panels and the color of the datapoints shows the
testing sample and the row of the panels shows the simulated number of causal
SNPs;
1019

1020
1021

1022
1023

Supplementary Figure 8: The relative increase PRS R^2 of DiscoDivas over
conventional PRS method when using the purely simulated validation data. Each panel
shows the performance of the two methods in each combination of validation sample
for the conventional PRS method and the testing sample; the horizontal bar show the
mean value of the relative increase; the color of the horizontal bar indicating mean
value of relative increase and p-value of the paired t-test of DiscoDivas PRS R^2 and
conventional PRS R^2, with cyan being the mean increase>0 and p-value<0.0005, dark
blue being mean increase>0 and p-value<0.05, dark red being mean increase<0 and
p-value<0.05, and grey being p-value>0.05
1033

1034
1035

Supplementary Figure 9: The PRS distance between individuals in testing samples to
the median point of the validation samples when including different numbers of PCA
in the distance calculation. Each panel shows the ancestry of the testing samples and
the color of the line shows the validation samples to which the distance is calculated.
The plot is based on 100 randomly selected individuals from each UKBB testing
sample.

1042
1043
1044